Scios merger talks
Executive Summary
Scios is in discussions with a "number of life sciences companies concerning potential strategic transactions," the company said in response to reports it is in merger talks with Johnson & Johnson. The transactions under discussion include a merger deal and partnership for Scios' rheumatoid arthritis oral p38 MAP kinase inhibitor program (Phase II SCIO-469 and Phase I SCIO-323). Scios has been previously touted as an acquisition target, given the success of the congestive heart failure drug Natrecor. J&J's recent acquisitions include Alza (2001) and Centocor (1999)...
You may also be interested in...
J&J Buys Scios: Will Natrecor Make Another Centocor?
Johnson & Johnson will gain access to Scios' Phase II oral rheumatoid arthritis program through its proposed $2.4 bil. acquisition of the biotech company
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.